Condition

Prostate Small Cell Neuroendocrine Carcinoma

ClinicalTrials.gov condition label

Clinical trials2

Recruiting0

Common interventions17

Lead sponsors shown2

Clinical trials

2 shown

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate CancerNCT06094842 · 2025-04-15

WITHDRAWN

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate CancerNCT03649841 · 2020-06-29

TERMINATED

Common interventions

Abiraterone AcetateDRUG1 Antiandrogen TherapyDRUG1 BendamustineDRUG1 BiopsyPROCEDURE1 Biospecimen CollectionPROCEDURE1 Bone ScanPROCEDURE1 Bridge TherapyPROCEDURE1 Computed TomographyPROCEDURE1 CyclophosphamideDRUG1 EchocardiographyPROCEDURE1 FludarabineDRUG1 LeukapheresisPROCEDURE1 Multigated Acquisition ScanPROCEDURE1 PrednisoneDRUG1 Radiation TherapyRADIATION1 T-cell Receptor-engineered T-cellsBIOLOGICAL1 X-Ray ImagingPROCEDURE1

Leading sponsors

Fred Hutchinson Cancer Center1 University of Washington1

Trial status mix

TERMINATED1

WITHDRAWN1

Phase mix

PHASE11

PHASE21

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.